Keywords: Takeda, Amgen, Millennium, Motesanib, Ph III, Lung cancer, NSCLC
Takeda and Amgen NSCLC drug motesanib fails in Ph III
Article | 31 March 2011
Top-line results from the MONET1 pivotal Phase III trial evaluating motesanib administered in combination with paclitaxel and carboplatin in 1,090 patients ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
